Leap Therapeutics, Inc. (LPTX)
| Market Cap | 132.44M |
| Revenue (ttm) | 1.13M |
| Net Income (ttm) | -38.87M |
| Shares Out | 76.32M |
| EPS (ttm) | -0.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $2.21 |
| Previous Close | $2.22 |
| Change ($) | -0.01 |
| Change (%) | -0.45% |
| Day's Open | 2.21 |
| Day's Range | 2.14 - 2.24 |
| Day's Volume | 433,464 |
| 52-Week Range | 1.17 - 2.94 |
CAMBRIDGE, Mass., Dec. 22, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced ...
CAMBRIDGE, Mass., Nov. 23, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced ...
CAMBRIDGE, Mass., Nov. 10, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced ...
CAMBRIDGE, Mass., Nov. 9, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced t...
Two new breakout stocks for Week 46 with better than 10% short-term upside potential. This past week three out of four stocks gained more than 10% closing with gains to Friday with AVNS +8.54%...
CAMBRIDGE, Mass., Sept. 24, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...
CAMBRIDGE, Mass. and BEIJING, Sept. 21, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and...
CAMBRIDGE, Mass., Sept. 9, 2020 /PRNewswire/ -- Leap Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 13, 2020 /PRNewswire/ -- Leap Therapeutics, Inc.
CAMBRIDGE, Mass., June 25, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...
CAMBRIDGE, Mass., June 17, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced ...
Leap Therapeutics (LPTX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
CAMBRIDGE, Mass., June 11, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced ...
CAMBRIDGE, Mass., June 11, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...
CAMBRIDGE, Mass., May 14, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported f...
Facing a de-listing from NASDAQ and forced to abandon its second clinical asset due to a cash crunch, Leap has rebounded somewhat on the back of a collaboration/financing deal.
Leap Therapeutics (LPTX) signs agreement with China-based BieGene granting the latter rights to develop its pipeline candidate, DKN-01. It also signs equity financing deals worth $27 million.
Leap Therapeutics (LPTX) news for Friday has LPTX stock soaring following a major deal with BeiGene for its DKN-01 antibody. The post Leap Therapeutics News: LPTX Stock Takes a Massive 58% Le...
Cross the age-old barrier of low P/E investing. bet on these five stocks that boast rising P/E.
Biotech stocks had an upweek, with the release of clinical trial results and the positive broader market sentiment offering ample support.
About LPTX
Leap Therapeutics, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. The company's clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. Its clinical stage programs also include TRX518, a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. The compa... [Read more...]
| Industry Biotechnology | Founded 2011 |
| CEO Douglas E. Onsi J.D. | Employees 24 |
| Stock Exchange NASDAQ | Ticker Symbol LPTX |
Analyst Forecasts
According to 5 analysts, the average rating for LPTX stock is "Buy." The 12-month stock price forecast is 5.10, which is an increase of 130.77% from the latest price.